Last update 01 Nov 2024

LNS-8801

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl] ethanone
Target
Mechanism
GPER1 agonists(G protein-coupled estrogen receptor 1 agonists)
Inactive Indication
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC21H18BrNO3
InChIKeyVHSVKVWHYFBIFJ-HKZYLEAXSA-N
CAS Registry-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Melanoma, Cutaneous MalignantPhase 3-01 Nov 2024
Unresectable MelanomaPhase 3-01 Nov 2024
Advanced cancerPhase 2
US
21 Oct 2019
Solid tumorPhase 2
US
21 Oct 2019
LymphomaPhase 1
US
21 Oct 2019
Pancreatic CancerPhase 1
US
08 Sep 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
germline GPER
9
jfisilhtmn(rqmcdtohsn) = G3 and G1 aqajlkptwh (xmeqwiqvbc )
Positive
14 Sep 2024
Phase 1/2
Refractory Melanoma
consensus germline GPER
10
LNS8801 + pembrolizumab
itrtczzkyt(ikmlhpmjnd) = jlynsvlkit ekylxcajfc (oriklwoojl )
Positive
02 Nov 2023
Phase 1/2
-
LNS8801 (125 mg, QD, PO) + Pembrolizumab (200 mg, Q3W, IV)
(sazlskmlgq) = opvwpgqydp upqbmbkezg (dgyshdtqvk )
-
22 Oct 2023
Phase 1/2
15
(jkoypjbrlp) = 4 of 8 monotherapy patients had AEs potentially related to study drug (all grade 1), with no AEs occurring in more than one patient. 6 of 7 combination patients had AEs potentially related to study drugs (grades 1-2), with fatigue occurring in more than one patient. kuhvoumkfj (xyzufscoix )
Positive
31 May 2023
LNS8801 125 mg+pembrolizumab 200 mg
Phase 1/2
13
LNS8801+Pembrolizumab
(nxzydjihkg) = LNS8801 was identified as 125 mg daily as a monotherapy and in combination with pembrolizumab (200 mg every 3 weeks) wwgduznlui (dzybkbmvks )
Positive
06 Jun 2022
Phase 1
13
LNS8801 125 mg+pembrolizumab 200 mg
(nflfwbwvom) = ounkskrdxr fnxmwlwhjq (babvhqwuai )
Positive
02 Jun 2022
Phase 1
33
(tbxlbhqasn) = evjwdagzow wvfhsciyfe (rpgedvxbcw )
Positive
20 May 2021
LNS8801+pembrolizumab
(tbxlbhqasn) = qiefzbclei wvfhsciyfe (rpgedvxbcw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free